Introduction
The flavin-containing monooxygenases (FMOs, EC 1.14.13.8) belong to a family of NADPH-, FAD-, and O 2 -dependent microsomal enzymes that catalyze the oxidation of a wide variety of nucleophilic heteroatom compounds containing a nitrogen, sulfur, phosphorous, or selenium atom (Krueger and Williams, 2005) . Eleven human FMO genes (FMO1 to FMO11P) have been identified to date, but human FMO1 through FMO5 are the only protein coding genes, which have been functionally characterized (Yamazaki and Shimizu, 2013) . Members of the FMO gene family display distinct temporal-, tissue-, and species-specific expression patterns (Klick and Hines, 2007) . Typical FMO substrates include trimethylamine, catecholamines (Turkanoglu Ozcelik et al., 2013) , nicotine (Bloom et al., 2013) , imipramine (Wagmann et al., 2016) , prothipendyl (Krueger and Williams, 2005) , amitriptyline (Krueger and Williams, 2005) , phospho-sulindac amide (Xie et al., 2014) , benzydamine (BZD) (Taniguchi-Takizawa et al., 2015) , ranitidine (Overby et al., 1997) , tamoxifen (Parte and Kupfer, 2005) , clozapine (Tugnait et al., 1997) , diphenhydramine (Cruciani et al., 2014) , amphetamine and methamphetamine (Cashman et al., 1999) .
FMO3, a protein with 532 amino acids, is the predominant form of the FMO enzyme family expressed in adult human liver (Yamazaki and Shimizu, 2013) . Although the FMO3 protein content is high in the liver Overby et al., 1997) , comparable to cytochrome P450 enzymes (CYPs) (Koukouritaki et al., 2007) , the role of FMO3 in xenobiotic or endobiotic metabolism has been often overlooked. The overlapping substrate specificity between FMO3 and CYPs, the thermal instability of the enzyme during in vitro incubation (Cashman, 2008) and the un-availability of selective FMO inhibitors are some of reasons of why contributions of FMO3 to drug biotransformation has not been studied more extensively. Further, many oxidation reactions previously found to be catalyzed by CYPs were later determined to be catalyzed solely or predominately by FMO3 (e.g., itopride, clozapine and cimetidine) (Cashman et al., 1993; Tugnait et al., 1997; Mushiroda et al., 2000) .
It has recently been concluded that FMOs are responsible for about 2.2% of all metabolic reactions and about 6% of all the phase I metabolic reactions (Testa et al., 2012) . Therefore, FMO3 is considered to be primarily responsible for almost all FMO-mediated reactions of pharmaceutical interest.
Unlike the CYPs, FMO3 is not generally induced or inhibited by xenobiotics (Klick and Hines, 2007) and therefore poses limited drug-drug interaction potential (Cashman, 2008) .
However, inter-individual differences in FMO3 activity (Overby et al., 1997) could result in significant differences in the FMO3-dependent biotransformation of exogenous and endogenous compounds, leading to unexpected drug reactions or pathological consequences (Koukouritaki et al., 2005) . Many single nucleotide polymorphisms (SNPs) are associated with FMO3 function (Mitchell and Smith, 2001; Zhou and Shephard, 2006; Phillips and Shephard, 2008) ; however, the mechanism is unclear whether these SNPs affect substrate affinity (K m ) or FMO3 protein levels. Moreover, some of the FMO3 SNPs exhibit linkage disequilibrium (LD) (Cashman and Zhang, 2002) ; but a systematic classification of haplotypes and diplotypes of FMO3 and their associations with protein activity or abundance have not been established. Although the association of the non-genetic factors, such as age and gender, with FMO3 abundance have been studied previously (Koukouritaki et al., 2002; Shimizu et al., 2011) , investigations with multiple samples and with a more precise method for protein quantification are needed. Therefore, the current study investigated the effect of genetic variations, and non-genetic factors including age, gender and ethnicity on FMO3 hepatic abundance utilizing liquid
chromatography-tandem mass spectrometry (LC-MS/MS). The investigation was conducted
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Materials and Methods

Chemicals and Reagents
Iodoacetamide (IAA), dithiothreitol (DTT), and pierce trypsin protease (MS grade) were purchased from Thermo Fisher Scientific (Rockford, IL). Ammonium bicarbonate buffer (ABB, 98% purity) was purchased from Acros Organics (Geel, Belgium). Chloroform, MS-grade acetonitrile (99.9% purity), methanol and formic acid (≥99.5% purity) were purchased from Fischer Scientific (Fair Lawn, NJ). Human serum albumin (HSA) and bovine serum albumin (BSA) were obtained from Calbiochem (Billerica, MA) and Thermo Fisher Scientific (Rockford, IL), respectively. Synthetic isotopically pure heavy stable isotope-labeled peptides were produced by Thermo Fisher Scientific (Rockford, IL). The purified recombinant FMO3 protein was obtained from Abnova (Walnut, CA; Catalog #: H00002328-P01). NADPH and BZD were purchased from Sigma-Aldrich (St. Louis, MO).
BZD N-oxide and dazidamine were obtained as previously described (Yeung et al., 2007) .
Human Liver Microsome Samples
Previously isolated human liver microsomes (HLM) (Pearce et al., 2016; Shirasaka et al., 2016) were used in this study. The liver tissue samples for the microsomal preparation were originally received from three liver banks: (1) (Prasad et al., 2014; Shirasaka et al., 2016; Boberg et al., 2017; Tanner et al., 2017 Supplementary Fig. 1 ). HLM samples were diluted to 2 mg/mL, and 80 μL (160 µg) microsomal protein (or purified FMO3
protein as calibrator) were digested as described previously (Boberg et al., 2017) 
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9 ABB buffer (100 mM) at 95°C for 10 min with gentle shaking at 300 rpm. After cooling to the room temperature for 10 minutes, the denatured protein was alkylated by the addition of 20 μL of 500 mM IAA; the reaction was carried out in the dark for 30 minutes. Ice-cold methanol (500 µL ), chloroform (100 µL ) and water (400 µL ) were added to each sample.
After vortex-mixing and centrifugation at 16,000 × g (4°C) for 5 minutes, the upper and lower layers were removed using vacuum suction and the pellets were dried at room temperature for 10 minutes. The pellets were then washed with 500 µL ice-cold methanol and subjected to centrifugation at 8000 × g (4°C) for 5 minutes. After the supernatant was removed, the pellets were dried at room temperature for 30 minutes and re-suspended in 60 µL ABB buffer (50 mM, pH 7.8). Subsequently, the protein pellets were digested by adding Table 2 . The LC-MS/MS data were processed using Analyst 1.6.2 version software (PE Sciex, Ontario, Canada).
FMO3 mRNA Quantification
FMO3 mRNA expression was only quantified in a subset of unprocessed liver tissue samples (n=214, Supplementary Table 1) . Details of the RNA-seq procedures including RNA isolation, truSeq stranded mRNA preparation, and read processing and analysis pipeline were described previously (Tanner et al., 2017) . The transcript levels of mRNA are displayed in FPKM (fragments per kilobase per million reads) values.
FMO3 Enzyme Activity Assay
FMO3 enzyme activity was performed on a limited number of HLM samples prepared from fresh liver tissues (donor age range from 9 to 68 years; mean±SD, 40.1±17.9 years, n=37, Supplementary Table 1) due to the potential instability of the protein to freeze-thaw cycles (Cashman, 2008) . The activity was determined by quantifying the rate of BZD N-oxidation (Stormer et al., 2000) . The assay conditions include: 0.2 mg/mL HLM protein, 0.1 M phosphate buffer (pH 7.4), 50 μM BZD, 0.5 mM NADPH, and water to a final volume of 250 μL. All reactions were performed in triplicate. Following a pre-incubation of 3 min at 37 °C, the reaction was initiated with the addition of substrate and allowed to continue with gentle agitation (70 rpm) for 20 min. The reaction was quenched with an equal volume of acetonitrile containing 0.1 mg/mL dazidamine (internal standard). Incubations were then placed on ice for 5 minutes to allow for full protein precipitation prior to centrifugation (14,000 rpm × 5 min). The supernatant was analyzed by an optimized HPLC method as reported previously (Yeung and Rettie, 2006) . Briefly, chromatographic separations of BZD, 
FMO3 Gene-resequencing, Genotyping and Haplotypes Determination
Two different approaches, gene-resequencing or genotyping, were used for genetic characterization of the liver donors because these data were generated in two different institutes (Supplementary Table 1 ). FMO3 gene-resequencing was performed using the PGRN-Seq platform, a targeted sequencing approach, for the University of Washington and St. Jude Liver Bank samples, as discussed elsewhere (Gordon et al., 2016) . DNA of the tissues provided by Children's Mercy were genotyped on the PharmacoScan (Affymetrix, Santa Clara, CA, USA). LD analysis of FMO3 variants and inferred haplotypes were determined using Haploview 4.2 (Cambridge, MA, USA).
Data Analysis
We used a robust strategy to ensure optimum reproducibility when quantifying FMO3
proteins. For example, ion suppression was addressed by using heavy peptide internal standards. BSA was used as exogenous protein internal standards, which was added to each sample as a fixed quantity before methanol-chloroform-water extraction and trypsin digestion.
Addition of BSA addresses the variability introduced during the pre-digestion processing
This article has not been copyedited and formatted. The final version may differ from this version. A nonlinear regression equation (Equation 1) was used to fit the ontogeny data, as described previously (Boberg et al., 2017) , where Adult max is the maximum average relative protein abundance, Age is the age in years of the subject at the time of sample collection, Age 50 is the age in years at which half-maximum adult protein abundance is obtained, F is the fractional protein abundance in adult samples, F birth is the fractional protein abundance (of adult) at birth, and n is the exponential factor. Supplementary Fig. 2 ). The lower limit of quantification for the FMO3 protein standard in the trypsin digestion buffer was 3.99 fmol (on-column). The intra-day precision (% coefficient of variance) of the analytical method, based on pooled quality control samples, was within 25%.
The average human liver FMO3 protein concentration in HLM samples (n=445) Fig.1 ). However, the correlation between FMO3 mRNA and protein abundance was poor (r=0.19, P>0.05) (data not shown).
Association of Non-genetic Factors with Human Hepatic FMO3 Abundance
Age was positively associated with FMO3 protein abundance. Stratifying by age as a categorical variable, the FMO3 protein abundance was 1.9-fold (P < 0.001) higher in adults compared to neonates (0-1 year) ( Fig. 2A) . Similarly, FMO3 abundance in neonatal liver was significantly lower compared to that observed in middle childhood (6-12 years, P < 0.01) and adolescence (12-18 years, P < 0.001). FMO3 protein levels were lower in infants (1-6 years, Fig. 3B ) as compared to males. The gender difference in both protein and mRNA levels were consistent even when pediatric samples below 6 years of age were excluded from the analysis (Supplementary Fig. 3 ). However, no significant difference in FMO3 activity was observed between female and male samples perhaps due to the small number of samples (data not shown).
No significant difference of FMO3 protein abundance was observed among Caucasians (25.4±12.4 pmol/mg protein, n=352) and African Americans (22.1±14.1 pmol/mg protein, n=30). (Fig. 4) . These SNPs include three missense (rs2266782, E158K; rs909530, N285N; and rs2266780, E308G) and three intronic (rs2064074, rs28363536, and rs909531) SNPs. However, there was no association between FMO3 mRNA expression and BZD N-oxidase activity among those SNPs that showed a correlation with protein abundance ( Supplementary Figs. 4 and 5).
Association of Genetic Factors with Human Hepatic FMO3 Abundance
To avoid false positive associations between these variants and FMO3 levels, LD analysis was subsequently performed. All SNPs within FMO3 were in HWE (P>0.05, Table 1 ).
Haplotype blocks and haplotypes were inferred based on the allele frequencies of the SNPs by using Haploview. In total, two haplotype blocks (Fig. 5) and six haplotypes, which occurred at a frequency greater than 1% accounting for more than 98.5% of the total chromosomes examined, were identified (Table 2) . Six SNPs (rs2266782, rs909530, rs2266780, rs2064074, rs28363536, and rs909531), which were associated with FMO3 abundance, were found in strong LD (D'>0.975) with each other, except between rs2266782
and rs909530, where a median LD (D'=0.632) was observed. Regression coefficients (r 2 ) of these pair-wise SNPs indicated that rs28363536, rs2266780 (E308G) and rs909531 tag the same haplotype (r 2 >0.97); rs2266782 (E158K) was associated with rs22064074 (r 2 =0.78);
and rs2266780 (E308G) was associated with rs909530 (N285N) (r 2 =0.71).
Diplotype-dependent protein abundance of FMO3 was observed after excluding the effect of ontogeny. Samples (with donor age over 6 years) harboring the H3 haplotype, which consist of six SNPs, had up to 50% lower FMO3 protein levels as compared to the reference haplotype H1 (Fig. 6) . The association between H3 haplotype and FMO3 activity could not be investigated because of the smaller number of samples and higher variability (data not Table 3) . Since genotyping was performed on a different platform, the comprehensive Haploview analysis described above for the adult samples could not be performed on the pediatric samples. However, consistent with the data described above, two SNPs, rs2266782
(E158K) and rs2266780 (E308G), showed associations with protein abundance (Supplementary Figs. 6A and 6B) . No associations were detected for other variants, which is possibly due to the low variant frequencies and/or confounding age-related variability.
Furthermore, the impact of haplotype E158K-E308G on FMO3 protein abundance was shown in Supplementary Fig. 6C . Considering the impact of allelic variants on FMO3 abundance, the association between age and human hepatic FMO3 protein was reanalyzed.
Age-dependent protein abundance of FMO3 was still observed after excluding the samples harboring the homozygous E158K-G308G. The FMO3 protein abundance was 2.2-fold (P < 0.001) higher in adults compared to neonates (0-1 year) (Fig. 2C ). After six years of age, there was no significant difference in FMO3 abundance between children and adults. FMO3
protein was 50% of the values observed in adults by approximately 15 months based on the reanalysis of the data (Fig. 2D ).
Discussion
In the present study, several genetic and non-genetic factors that contribute to variation in human hepatic FMO3 were identified in a large cohort of samples (n=445). Although FMO quantification in the human livers has been accomplished by Western blotting and LC-MS/MS in previous studies (Overby et al., 1997; Chen et al., 2016) , the sample sizes were small (n=5-10) in these studies and the associations of genetic factors as well as the interplay of ontogeny and genotype were not investigated. Consistent with the reported data based on the immunoblotting method (Koukouritaki et al., 2002; Shimizu et al., 2011) , an age-dependent increase in FMO3 protein levels was also observed in this study (Fig. 2) .
Koukouritaki et al. found that FMO3 expression increased 4.5-fold between three weeks and 10 months (1.1 pmol/mg protein to 4.7 pmol/mg protein), with another approximate 3-fold between 10 months and 11 years (4.7 pmol/mg protein to 12.7 pmol/mg protein) (Koukouritaki et al., 2002) . Between 11 and 18 years of life, there was a third significant increase in mean expression levels (12.7 pmol/mg protein to 26.9 pmol/mg protein) (Koukouritaki et al., 2002) . In the present study, only a 2-fold increase in mean FMO3 abundance was observed between infancy (0-1 year) and middle childhood (6-12 years), and no significant increase was found in the donors over 6 years of age. However, the hepatic FMO3 levels found in both studies were comparable (24.2 vs. 26.9 pmol/mg protein) in adolescence. Differences in sensitivity at lower concentrations between Western blotting and LC-MS/MS methods, age classification criteria, quality of samples and data analysis (3-17% of samples in each age group were excluded in the study by Koukouritaki et al) may explain, at least in part, the differing observations between studies.
An association between gender and hepatic FMO3 levels has not been revealed in previous reports (Cherrington et al., 1998; Koukouritaki et al., 2002) . In this study, we 
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19 observed a modest, statistically significant (but perhaps not clinically relevant) gender difference in FMO3 mRNA and protein abundances (Fig. 3) , perhaps because of the larger number of samples tested and increase statistical power. Previous studies have shown that female mouse livers contain higher levels of FMO3 mRNA levels (80-fold) than those in male liver samples (Janmohamed et al., 2004) . This may be due to the modulating effects of testosterone on FMO3 expression; testosterone but not 17-estradiol suppresses mouse FMOs hepatic activity (dimethylaniline N-oxidation) (Duffel et al., 1981) . Following castration, hepatic FMO activity (methimazole oxidation) increased significantly and serum testosterone levels decreased; however, administration of physiological levels of testosterone to castrated animals returned FMO activity (Falls et al., 1997) . However, there is little evidence for sex hormone-regulation of the FMO3 abundance in human liver. While gender difference was apparently observed for FMO3 mRNA as well as the protein expression, the regression analysis indicated lack of correlation between FMO3 mRNA and protein expression, in consistent with the previous study (Overby et al., 1997) . The latter indicates that FMO3 mRNA is not a good surrogate of its protein abundance. This lack of association could be a result of different mechanisms of mRNA and protein regulation (Liu et al., 2016) or mRNA instability in the frozen-thawing procedure of the samples (Botling et al., 2009 ).
More than 300 SNPs have been reported for FMO3 (http://www.ncbi.nlm.nih.gov). Most are rare and over 40 of these polymorphisms have been linked to altered FMO3 function and symptomatic trimethylaminuria (also referred as "fish-like odor syndrome") (Yeung et al., 2007) . FMO3 variants have also been associated with higher risks of sudden infant death syndrome (Poetsch et al., 2010) and hypertension-related ischemic stroke (Turkanoglu Ozcelik et al., 2013) , altered cigarette consumption (Bloom et al., 2013) , and increased efficacy of sulindac to prevent familial adenomatous polyposis (Hisamuddin et al., 2004) . In This article has not been copyedited and formatted. The final version may differ from this version. Lattard et al., 2003; Yamazaki and Shimizu, 2013) ; but changes in K m are substrate-dependent (Lattard et al., 2003; Yeung et al., 2007) . These results indicate that the effects of nonsynonymous variants on FMO3 substrate affinity may be substrate-dependent, but their effects on FMO3 abundance are consistent. However, direct evidence of the association between genetic variation and FMO3 protein abundance has never been studied.
In the present study, six SNPs were identified that are associated with decreased FMO3 protein expression. Individuals homozygous for the missense variant allele E158K
(rs2266782) was associated with significantly lower FMO3 protein levels (Fig. 4) , which was consistent with the 65% reduced FMO3 catalytic efficiency (V max /K m ) in vitro towards multiple substrates such as methimazole, trimethylamine and 10-(N,N-dimethylaminopentyl)-2-(trifluoromethyl) -phenothiazine) (Lattard et al., 2003) . Similarly, a positive association between protein abundance and activity was observed for another amino acid change, E308G, caused by rs2266780 (Lattard et al., 2003) . Two other variants, P153L (rs72549326) and E305X (rs61753344), previously shown to have no functional activity (Treacy et al., 1998; Yeung et al., 2007) , could not be tested in this study because of the lack of sufficient samples.
Albeit, the FMO3 abundance was lower (11.8 and 7.8 vs. 26.4 pmol/mg protein for P153L and E305X vs. reference allele, respectively) in the single heterozygous sample present in our cohort. Similarly, another function-unchanging missense SNP, V257M (rs1736557) (Treacy et al., 1998) , showed no relation to FMO3 protein levels in this study. Several mechanisms could potentially explain decreased protein levels as a result of inherited alterations in encoded amino acid sequence, but the mechanism has most often involved accelerated JPET #243113 21 degradation of the variant allozyme, which is typically via an ubiquitin-proteasome-mediated pathway (Weinshilboum and Wang, 2004) . Furthermore, one synonymous SNP (N285N, rs2266780) and three intronic variants (rs2064074, rs28363536, and rs909531) were also associated with the decreased FMO3 protein abundance (Fig. 4) . Although synonymous SNPs and variants in intronic regions may also contribute to changes in protein abundance by impacting splicing, translation fidelity, mRNA stability and protein folding (Sauna and Kimchi-Sarfaty, 2011) , no correlation between FMO3 function and these SNPs has been reported. Three samples showed relatively high FMO3 protein levels but very small BZD N-oxidation activity (Fig. 1) . The potential mechanism of the disconnection between FMO3
protein levels and activity might be the instability of FMO3 protein or unique functional variant not investigated in the present study.
LD analysis data showed that SNP rs2266780 (N285N), rs2064074, rs28363536, and rs909531 is perhaps related to E308G and/or E158K, indicating that the suppressive impacts of these fours SNPs on FMO3 protein abundance may be from one or both of the exonic SNPs. Moreover, consistent with previous studies which reported that V max of FMO3 were
Wild-type > E158K ≈ E308G > E158K-E308G (Lattard et al., 2003; Krueger and Williams, 2005) , the FMO3 protein abundance of a donor homozygous for haplotype E158K-E308G, was found to be significantly lower than the reference allele in this study ( Fig. 6 and Supplementary Fig. 6 ). This is the first direct evidence that the decreased FMO3 protein abundance in liver tissues from donors harboring these SNPs (E158K and E308g variants) is one of the possible reasons for a significant reduction in FMO3 activity.
There were a number of limitations in this study. For instance, although we determined protein levels of FMO3 in 445 samples, we were only able to access 37 fresh samples and only one typical substrate was used to measure enzyme activity; this sample size was 
